Blog
RSS FeedPosted by Michael Wonder on 04 Aug 2017
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
4 August 2017 - Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as ...
Posted by Michael Wonder on 04 Aug 2017
Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE
4 August 2017 - NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and ...
Posted by Michael Wonder on 03 Aug 2017
UK finds Roche bladder cancer drug too costly for routine use
3 August 2017 - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for daratumumab
3 August 2017 - CADTH has published its initial recommendation on the use of daratumumab for use in combination with ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for Keytruda
3 August 2017 - CADTH has published its initial recommendation on the use of pembrolizumab for use by untreated patients ...
Posted by Michael Wonder on 03 Aug 2017
Negative NICE draft guidance for Lutathera
3 August 2017 - UK medicines cost-effectiveness watchdog NICE has today published draft guidance which does not recommend French molecular nuclear ...
Posted by Michael Wonder on 03 Aug 2017
Call to strip government subsidies from 'junk' health insurance
4 August 2017 - Consumer advocacy group CHOICE has called on the federal government to stop providing tax breaks and ...
Posted by Michael Wonder on 03 Aug 2017
Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases
2 August 2017 - Positive recommendation moves Erelzi closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 03 Aug 2017
Biosimilar Renflexis (infliximab) available on PBS from 1st August
1 August 2017 - Infliximab biosimilar to be dispensed predominately through hospitals. ...
Posted by Michael Wonder on 02 Aug 2017
NIB’s Mark Fitzgibbon calls for ‘single payer’ in healthcare
3 August 2017 - Health insurer NIB has called on the Turnbull government to trial a “single payer” model for ...
Posted by Michael Wonder on 02 Aug 2017
Roche invited to submit a CDF proposal for urothelial cancer drug
2 August 2017 - NICE has asked Roche to submit a Cancer Drugs Fund proposal for an immunotherapy treatment called ...
Posted by Michael Wonder on 02 Aug 2017
Review fundamentally flawed
2 August 2017 - The Pharmacy Remuneration and Regulation Review (the King Review) has been hijacked by a combination of ...
Posted by Michael Wonder on 01 Aug 2017
Sharing patient input submissions for the CDR program
1 August 2017 - Since February 2014, CADTH has shared patient input submissions on our website, when permission has been ...
Posted by Michael Wonder on 01 Aug 2017
Proposed revisions to CADTH’s biosimilar review process
1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...
Posted by Michael Wonder on 01 Aug 2017
Private health cover forecast to become more unaffordable as insurers, doctors point finger
1 August 2017 - Do you have private health insurance? Are you considering cancelling or downgrading it because you can't ...